Sort   by:  
 Page size 
MetabolomicsTargeting PI3K inhibitor resistance in breast cancer with metabolic drugs

Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2-) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly improves ...

2026-08-21 | MTBLS11671 | MetaboLights
MetabolomicsSerum metabolomic profiles identify ER-positive early breast cancer patients at increased risk of disease recurrence in a multicentre population

PURPOSE: Detecting signals of micrometastatic disease in early breast cancer (EBC) patients could improve risk stratification and allow better tailoring of adjuvant therapies. We have previously shown that postoperative serum metabolomic profiles are predictive of relapse in a si...

2017-03-02 | MTBLS424 | MetaboLights
MetabolomicsExploring Lipidomic Profiles and Their Correlation with Hormone Receptor and HER2 Status in Breast Cancer
Dysregulated lipid metabolism promotes the progression of various cancers, including breast cancer. This study aimed to explore the lipidomic profiles of breast cancer patients, providing insights into the correlation between lipid compositions and tumor subtypes characterized by hormone receptor (H...
2024-08-16 | MTBLS10858 | MetaboLights
MetabolomicsMonounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients
Changes in cellular lipid metabolism are a common feature in most solid tumors, which occur already in early stages of the tumor progression. However, it remains unclear if the tumor-specific lipid changes can be detected at the level of systemic lipid metabolism. The objective of this study was to ...
2014-06-17 | MTBLS92 | MetaboLights
TranscriptomicsmRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer
The intention was to detect genes that are determining trastuzumab efficiency in HER2-positive breast cancer cell lines with different resistance phenotypes. While BT474 should be sensitive to the drug treatment, HCC1954 is expected to be resistant due to a PI3K mutation. The cell line BTR50 has bee...
ORGANISM(S): Homo sapiens 
2015-04-21 | E-GEOD-55005 | biostudies-arrayexpress
TranscriptomicsAn Integrated Model of the Transcriptome Landscape of HER2-Positive Breast Cancer
The goal of our study is to build an integrated transcriptome landscape model for HER2 positive breast tumors and identify the crucial signaling pathways associated with HER2 tumors. Genomic features include, 685 genes that were differentially expressed only in HER2-positive tumors, 102 genes that w...
ORGANISM(S): Homo sapiens 
2013-12-06 | E-GEOD-45419 | biostudies-arrayexpress
ProteomicsMapping the anti-cancer activity of alpha-connexin carboxyl-terminal (aCT1) peptide in resistant HER2+ breast cancer
Connexin 43 (Cx43) is a protein encoded by the GJA1 gene and is a component of cell membrane structures called gap junctions, which facilitate intercellular communication. Prior evidence indicates that elevated GJA1 expression in the HER2-positive (HER2+) subtype of breast cancer is associated with ...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2023-12-01 | MSV000093550 | MassIVE
ProteomicsProteomic maps of breast cancer subtypes
Systems-wide profiling of breast cancer has so far built on RNA and DNA analysis by microarray and sequencing techniques. Dramatic developments in proteomic technologies now enable very deep profiling of clinical samples, with high identification and quantification accuracy. We analyzed 40 estrogen ...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2017-03-29 | MSV000080757 | MassIVE
TranscriptomicscaArray_harri-00137: Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer
To assess pathologic complete response (pCR), clinical response, feasibility, safety, and potential predictors of response to preoperative trastuzumab plus vinorelbine in patients with operable, human epidermal growth factor receptor 2 (HER2)-positive breast cancer. EXPERIMENTAL DESIGN: 48 patients ...
ORGANISM(S): Homo sapiens 
2015-06-25 | E-GEOD-70233 | biostudies-arrayexpress
ProteomicsIdentification of strategies to overcome resistance in HER2 positive breast cancer.
The use of trastuzumab and pertuzumab in combination with docetaxel for initial treatment of HER2-positive breast cancer patients has resulted in notable clinical benefits in comparison to docetaxel administered with trastuzumab alone. Nevertheless, although therapeutic success is evident at the out...
ORGANISM(S): Homo sapiens (Human) 
2024-01-26 | PXD045804 | Pride
Breast cancer  her2-positive  targeted therapy  trastuzumab  pertuzumab  resistance  label-free proteomics. 
Sort   by:  
 Page size